Clinical trial readout dates for Vertex Pharmaceuticals Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is January 2027.
The registry reports these trials have finished collecting primary data. Results often follow within months, and the company may already have reported.
| Phase 2 Inaxaplin Proteinuric Kidney Disease · NCT06794996 | July 2026 Primary data collected |
| Phase 3 Suzetrigine Diabetic Peripheral Neuropathic Pain · NCT06696443 | January 2027 Ongoing |
| Phase 1/2 VX-670 Myotonic Dystrophy Type 1 (DM1) · NCT06185764 | February 2027 Ongoing |
| Phase 1/2 VX-264 Type 1 Diabetes · NCT05791201 | March 2027 Ongoing |
| Phase 2 VX-993 Diabetic Peripheral Neuropathic Pain · NCT06619860 | March 2027 Recruiting |
| Phase 3 ELX/TEZ/IVA Cystic Fibrosis · NCT05331183 | April 2027 Ongoing |
| Phase 3 Suzetrigine Diabetic Peripheral Neuropathic Pain · NCT07231419 | April 2027 Recruiting |
| Phase 3 Suzetrigine Diabetic Peripheral Neuropathic Pain · NCT06628908 | May 2027 Recruiting |
| Phase 3 CTX001 Sickle Cell Disease; Hydroxyurea Failure · NCT05329649 | June 2027 Ongoing |
Vertex Pharmaceuticals Inc. reported $9.82B in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-03). It reported net income of $654M for that quarter.
| 8-K Results of Operations — earnings, may carry pipeline updates | 2026-11-02 |